Cargando…

Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis

BACKGROUND: Sanqi Panax notoginseng injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang, Lin, Yan, Shi, Zhixiang, Hu, Yuxuan, Shao, Taihang, Li, Mengyuan, Zhu, Jiawen, Sun, Lizhou, Chang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506788/
https://www.ncbi.nlm.nih.gov/pubmed/34733959
http://dx.doi.org/10.21037/atm-21-782
_version_ 1784581761677656064
author Li, Yang
Lin, Yan
Shi, Zhixiang
Hu, Yuxuan
Shao, Taihang
Li, Mengyuan
Zhu, Jiawen
Sun, Lizhou
Chang, Feng
author_facet Li, Yang
Lin, Yan
Shi, Zhixiang
Hu, Yuxuan
Shao, Taihang
Li, Mengyuan
Zhu, Jiawen
Sun, Lizhou
Chang, Feng
author_sort Li, Yang
collection PubMed
description BACKGROUND: Sanqi Panax notoginseng injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze the published reports of efficacy and safety of Sanqi Panax notoginseng injection and safflower yellow injection for the treatment of acute cerebral infarction. The cost-effectiveness of these drug formulations was also evaluated. METHODS: China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, and the Chinese Biomedical Literature (CBM) were searched with the restrictions keywords in Chinese and English between 2006 and 2019 to obtain RCTs. A meta-analysis and a meta-regression analysis were undertaken in Reviewer Manager 5.3 software to compare the efficacy and safety of Sanqi Panax notoginseng and safflower yellow injection. This study used a decision tree model to analyze the cost-effectiveness of the two treatments. The TreeAge Pro software was used to comprehensively evaluate the economics of these medications. RESULTS: Twelve papers were all randomized controlled trials (RCTs) in which Sanqi Panax notoginseng injection was applied in the control group, while safflower yellow injection was applied in the experimental group and the quality of them were good. The results of the 12 papers were compared, and the total effective rate of the treatment group (91.18%) was significant and showed no significant difference with the control group (74.83%) (RR =1.24, 95% CI: 1.19, 1.30, P<0.00001). From the perspective of pharmacoeconomics, compared with Sanqi Panax notoginseng group, the ICER of safflower yellow injection is 3,885.75 RMB. The sensitivity analysis results were consistent with the basic analysis results, indicating that the basic analysis results were relatively stable. CONCLUSIONS: Comparing with Sanqi Panax notoginseng injection, safflower yellow injection and related combination therapy can improve the total effective rate and are safer with fewer adverse reactions. It is also more cost-effective than the use of Sanqi Panax notoginseng injection.
format Online
Article
Text
id pubmed-8506788
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-85067882021-11-02 Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis Li, Yang Lin, Yan Shi, Zhixiang Hu, Yuxuan Shao, Taihang Li, Mengyuan Zhu, Jiawen Sun, Lizhou Chang, Feng Ann Transl Med Original Article BACKGROUND: Sanqi Panax notoginseng injection and safflower yellow injection were Chinese traditional medicine injections for the treatment of cardiovascular diseases and were used to treat acute cerebral infarction patients in public hospital widely. The aim of this study was to compare and analyze the published reports of efficacy and safety of Sanqi Panax notoginseng injection and safflower yellow injection for the treatment of acute cerebral infarction. The cost-effectiveness of these drug formulations was also evaluated. METHODS: China National Knowledge Infrastructure (CNKI), Wanfang, SinoMed, VIP, PubMed, Embase, and the Chinese Biomedical Literature (CBM) were searched with the restrictions keywords in Chinese and English between 2006 and 2019 to obtain RCTs. A meta-analysis and a meta-regression analysis were undertaken in Reviewer Manager 5.3 software to compare the efficacy and safety of Sanqi Panax notoginseng and safflower yellow injection. This study used a decision tree model to analyze the cost-effectiveness of the two treatments. The TreeAge Pro software was used to comprehensively evaluate the economics of these medications. RESULTS: Twelve papers were all randomized controlled trials (RCTs) in which Sanqi Panax notoginseng injection was applied in the control group, while safflower yellow injection was applied in the experimental group and the quality of them were good. The results of the 12 papers were compared, and the total effective rate of the treatment group (91.18%) was significant and showed no significant difference with the control group (74.83%) (RR =1.24, 95% CI: 1.19, 1.30, P<0.00001). From the perspective of pharmacoeconomics, compared with Sanqi Panax notoginseng group, the ICER of safflower yellow injection is 3,885.75 RMB. The sensitivity analysis results were consistent with the basic analysis results, indicating that the basic analysis results were relatively stable. CONCLUSIONS: Comparing with Sanqi Panax notoginseng injection, safflower yellow injection and related combination therapy can improve the total effective rate and are safer with fewer adverse reactions. It is also more cost-effective than the use of Sanqi Panax notoginseng injection. AME Publishing Company 2021-09 /pmc/articles/PMC8506788/ /pubmed/34733959 http://dx.doi.org/10.21037/atm-21-782 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, Yang
Lin, Yan
Shi, Zhixiang
Hu, Yuxuan
Shao, Taihang
Li, Mengyuan
Zhu, Jiawen
Sun, Lizhou
Chang, Feng
Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
title Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
title_full Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
title_fullStr Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
title_full_unstemmed Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
title_short Safflower yellow pigment and Sanqi Panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
title_sort safflower yellow pigment and sanqi panax notoginseng in the treatment of acute cerebral infarction: a systematic review, meta-analysis, and cost-effectiveness analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506788/
https://www.ncbi.nlm.nih.gov/pubmed/34733959
http://dx.doi.org/10.21037/atm-21-782
work_keys_str_mv AT liyang saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT linyan saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT shizhixiang saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT huyuxuan saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT shaotaihang saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT limengyuan saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT zhujiawen saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT sunlizhou saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis
AT changfeng saffloweryellowpigmentandsanqipanaxnotoginsenginthetreatmentofacutecerebralinfarctionasystematicreviewmetaanalysisandcosteffectivenessanalysis